RecruitingPersistent Pulmonary Hypertension of the Newborn
PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn
Eligible age
Up to 1 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to determine if normally occurring variations in a specific gene called PTGS-1 are associated with an increased risk of narrowing of the ductus arteriosus from exposure to over-the-counter pain medicines (NSAIDs).
Sponsor: Medical College of Wisconsin
You may qualify if…
- ✓ Infants born greater than or equal to 34 weeks gestational age diagnosed with PPHN and normal, healthy infants born greater than or equal to 34 weeks gestational age.
You may not qualify if…
- ✕ Patients will be excluded if they are diagnosed with lethal congenital anomalies
- ✕ structural congenital heart disease except presence of patent ductus arteriosus (PDA) or patent foramen ovale
- ✕ structural gastrointestinal tract abnormality that could interfere with meconium passage
- ✕ congenital anomalies such as diaphragmatic hernia, Potter's syndrome, or pulmonary hypoplasia
Where it's recruiting
Wisconsin
Milwaukee
Source: ClinicalTrials.gov · NCT00710177 · last updated 2026-01-26